Skip to content
Study details
Enrolling now

Gene Transfer Trial for Cancer

National Cancer Institute (NCI)
NCT IDNCT02830724ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

124

Study length

about 11 years

Ages

18–72

Locations

1 site in MD

What this study is about

This trial is testing a new way to treat cancer by modifying blood cells with a special gene. Researchers are giving these modified cells back to patients who have CD70-expressing cancers like breast, melanoma, ovarian, pancreatic, or renal cell cancer. The goal is to see if this treatment can safely shrink tumors and determine its safety.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Anti-hCD70 CAR transduced PBL
  • 2.Take Aldesleukin
  • 3.Take Cyclophosphamide
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

aldesleukin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine

Drug routes

infusion

Endpoints

Primary: Frequency and severity of treatment-related adverse events, Response rate

Secondary: Frequency and severity of treatment-related adverse events

Body systems

Oncology